Vertical: CNMBase Year: 2025
Market Size (2025)
$60.89M
Projected (2032)
$90.83M
CAGR (2022–2032)
5.9%
Key Players
10+
Market Overview
The Global Triazolinthione Intermediates Market was valued at USD 60.887 Million in 2025 and is projected to reach USD 90.833 Million by 2032, registering a CAGR of 5.87% over the forecast period 2026–2032. Between 2025 and 2032 the market is expected to add USD 29.946 Million in absolute value. Historically, the market expanded from USD 51.102 Million in 2022 to USD 54.187 Million in 2023 and USD 57.446 Million in 2024, reflecting steady downstream demand for triazolinthione-class fungicides and the progressive localisation of intermediate manufacturing in Asia.
Triazolinthione intermediates are the specialty chemical building blocks used to construct the 1,2,4-triazoline-3-thione ring system and its side-chain precursors, the defining structural feature of prothioconazole, the leading demethylation-inhibitor (DMI) fungicide in global cereals, oilseeds and soybean protection. Demand for these intermediates is therefore closely linked to the production volumes of prothioconazole technical material, which has expanded rapidly since the expiry of the core compound patents and the entry of a large number of Chinese and other generic producers from 2019 onward. The market is characterised by high technical barriers in chlorination, cyclopropanation and thione-ring-forming chemistry, tight impurity specifications set by technical-equivalence requirements, and a supply base that is heavily concentrated in China and, to a growing extent, India.
Growth over the forecast period is underpinned by rising fungicide intensity in wheat, barley, oilseed rape, corn and soybean; increasing disease pressure from Fusarium head blight, septoria leaf blotch, rusts and sclerotinia; resistance-management programmes that favour DMI-based mixtures; and the continuing shift of prothioconazole technical production toward generic manufacturers that purchase or integrate intermediate supply. These drivers are partly offset by severe price deflation in prothioconazole technical material, regulatory uncertainty in Europe and the environmental compliance burden associated with chlorinated and sulphur-based chemistry.
Key Findings
By Downstream Product: Prothioconazole is the largest segment, accounting for 90.0% of the market in 2025 (USD 54.798 Million), while Others is the fastest-growing segment with a CAGR of 7.13% during 2026–2032.
By Purity: The 98% & Above segment is the largest, with a 85.0% share in 2025 (USD 51.754 Million), and is also the fastest-growing segment, with a CAGR of 6.24%.
By Region: Asia Pacific is the leading region with a 78.0% share in 2025 (USD 47.492 Million), whereas Latin America is the fastest-growing region with a CAGR of 8.13%.
By Country: China is the leading country, valued at USD 27.545 Million in 2025, equivalent to 45.2% of the global market. Brazil is the fastest-growing country, with a CAGR of 8.41% during 2026–2032.
Absolute opportunity: Asia Pacific is expected to contribute USD 23.903 Million of incremental value between 2025 and 2032, the largest absolute gain of any region.
Segmentation Summary
The market is analysed by downstream product (Prothioconazole and Others), by purity (98% & Above and Below 98%) and by region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), with country-level analysis for 20 countries and country groupings. The downstream product segmentation is dominated by prothioconazole, which absorbs the bulk of global triazolinthione intermediate output; the Others segment, covering other triazolinthione-based agrochemical actives, metabolites, reference standards and research compounds, is smaller but expanding faster. By purity, intermediates of 98% & above dominate, because technical-equivalence assessments and tight limits on relevant impurities push prothioconazole producers toward high-purity inputs.
Competitive Landscape Summary
The competitive landscape is moderately fragmented and is undergoing structural change. Bayer AG, the originator of prothioconazole, retains the largest integrated production base and the strongest brand portfolio, while ADAMA Ltd. operates backward-integrated prothioconazole production that supplies its proprietary mixtures. The fastest capacity additions are coming from Chinese producers, notably Hailir Pesticides and Chemicals Group, Anhui Jiuyi Agriculture Co., Ltd., Ningxia Yifan Biotechnology, Jiangsu Changqing Agrochemical Co., Ltd., Jiangsu Suli Co., Ltd., ABA Chemicals Corporation and Hebei Xingbai Pharmaceutical Group, many of which are integrating backward into key intermediates. Specialist upstream suppliers such as Jiangxi Tianxin Pharmaceutical Co., Ltd., which is building large-scale α-acetyl-γ-butyrolactone capacity, are also positioning to serve the expanding technical base.
Challenges and Opportunities
The principal challenge is the gap between announced Chinese prothioconazole capacity and actual global demand, which has driven technical prices sharply lower since 2021 and is compressing margins along the intermediate chain. Producers also face rising environmental-compliance costs for chlorination, hydrazine handling and sulphur chemistry, and regulatory uncertainty in the European Union, where the renewal of prothioconazole approval remains pending under an extended approval period. Opportunities include supplying high-purity intermediates to new generic technical entrants that lack in-house upstream capability, serving fast-growing soybean and cereal markets in Latin America and South Asia, developing cleaner and higher-yield process routes, and capturing demand from new prothioconazole mixtures with SDHI and strobilurin partners.
Future Outlook
The market is expected to grow from USD 64.518 Million in 2026 to USD 90.833 Million in 2032. Asia Pacific will remain the manufacturing centre of the industry, while Latin America and Middle East & Africa are expected to record the highest growth rates on the back of rising fungicide use in soybean, corn and cereals. Competitive advantage will increasingly depend on process cost, impurity control, environmental performance and secure access to key upstream raw materials, and consolidation among smaller intermediate producers is likely as price pressure persists.
The Triazolinthione Intermediates Market market is projected to grow at a CAGR of 5.9% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Triazolinthiones are heterocyclic compounds containing a 1,2,4-triazole ring bearing a thione (C=S) group, typically present as the 2,4-dihydro-3H-1,2,4-triazole-3-thione tautomer. In crop protection, this structure defines the triazolinthione chemical subgroup of the DMI (demethylation inhibitor) fungicides, classified by the Fungicide Resistance Action Committee (FRAC) in Group 3, of which prothioconazole (2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione, CAS 178928-70-6) is the principal commercial active ingredient.
For the purpose of this study, triazolinthione intermediates are defined as the specialty chemical intermediates that are manufactured and traded specifically for the synthesis of triazolinthione active ingredients and related compounds. These include the cyclopropyl ketone building blocks (such as 1-chloro-1-acetylcyclopropane and 2-chloro-1-(1-chlorocyclopropyl)ethanone, which are themselves derived from α-acetyl-γ-butyrolactone), the substituted chlorophenyl–cyclopropyl propanol and oxirane intermediates, the hydrazino-alcohol intermediates, and the triazolidine-3-thione precursors that are oxidised to form the final triazolinthione ring.
Included: merchant and captive-transfer sales of the above intermediates, valued at the intermediate stage, across purity grades of 98% & above and below 98%, for use in prothioconazole and other triazolinthione-based products.
Excluded: finished prothioconazole technical material and formulated fungicide products; commodity reagents such as hydrazine hydrate, 1,2,4-triazole, thiocyanates and formaldehyde when sold for general industrial use; and triazole intermediates used exclusively for non-thione triazole fungicides such as tebuconazole or propiconazole.
Scope of the Study
The study covers the global market for triazolinthione intermediates, with values expressed in USD Million. Historic data are presented for 2022–2024, 2025 is the base year, and forecasts cover 2026–2032. Compound annual growth rates refer to the period 2026–2032. The market is segmented as follows:
By Downstream Product: Prothioconazole, Others
By Purity: 98% & Above, Below 98%
By Region: North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country-level coverage comprises North America (U.S., Canada, Mexico); Europe (Germany, U.K., France, Italy, Spain, Rest of Europe); Asia Pacific (China, India, Japan, Rest of Asia Pacific); Latin America (Brazil, Argentina, Rest of Latin America); Middle East & Africa (UAE, Saudi Arabia, South Africa, Rest of MEA).
Research Objectives
To estimate the size of the global triazolinthione intermediates market for 2022–2025 and forecast it for 2026–2032 in value terms (USD Million).
To analyse the market by downstream product and purity, and to quantify the dependence of intermediate demand on prothioconazole technical production.
To assess regional and country-level demand and supply patterns, with particular focus on China and India as manufacturing hubs and on Europe and the Americas as end-use markets.
To identify the drivers, restraints, opportunities, trends and challenges shaping the market, including patent expiry, capacity expansion and price deflation in prothioconazole technical material.
To examine the value chain from upstream raw materials such as α-acetyl-γ-butyrolactone, 2-chlorobenzyl chloride and hydrazine hydrate through to formulated fungicides.
To review the regulatory framework affecting the manufacture, trade and downstream use of triazolinthione intermediates in major regions.
To profile the competitive environment, including leading technical and intermediate producers, their positioning and their capacity and product developments since 2022.
To provide strategic insights for intermediate manufacturers, technical producers, formulators, traders and investors.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study follows a structured research process combining secondary research, primary research and analytical modelling. The process begins with defining the market scope and segmentation, followed by extensive desk research to build an understanding of prothioconazole chemistry, manufacturing routes, capacity, regulatory status and trade flows. Hypotheses developed from secondary research are then validated and refined through discussions with industry participants across the value chain. Market size estimates are built using both top-down and bottom-up approaches, triangulated, and then projected over the forecast period using a factor-based forecasting model.
Stage 1 – Scoping: definition of the product, segmentation framework, geographic coverage and timeline.
Stage 2 – Secondary research: collection of data on technical and intermediate capacity, production, trade, pricing, registrations and regulation.
Stage 3 – Primary research: validation of assumptions, pricing, purity mix and regional demand through industry discussions.
Stage 4 – Market estimation: top-down and bottom-up sizing, followed by data triangulation.
Stage 5 – Forecasting and validation: projection to 2032, internal quality review and final consistency checks.
Secondary Research
Secondary research for this market draws on sources specific to agrochemical active ingredients and fine-chemical intermediates, including:
Industry associations: CropLife International and regional affiliates, the China Crop Protection Industry Association (CCPIA), the Pesticide Manufacturers & Formulators Association of India (PMFAI), and the Fungicide Resistance Action Committee (FRAC).
Government and regulatory bodies: the Institute for the Control of Agrochemicals, Ministry of Agriculture and Rural Affairs of China (ICAMA), the European Food Safety Authority (EFSA) and the European Commission EU Pesticides Database, the U.S. Environmental Protection Agency (EPA), India's Central Insecticides Board & Registration Committee (CIB&RC), Brazil's Ministry of Agriculture and Livestock (MAPA), and environmental-impact-assessment disclosures by provincial authorities in China.
Company filings: annual reports, interim reports, investor presentations, IPO prospectuses and stock-exchange announcements of listed agrochemical and fine-chemical producers.
Trade journals and specialist media: agrochemical industry publications, Chinese pesticide market information services and fine-chemical trade press reporting on capacity, prices and registrations.
Trade and customs data: national customs statistics and international trade databases for relevant HS codes covering heterocyclic compounds and pesticide technicals.
Paid databases: company databases, patent databases and agrochemical market intelligence services.
Primary Research
Primary research was conducted to validate secondary findings and to fill information gaps. Discussions were held with participants on both the supply side and the demand side of the market through telephone interviews, online discussions and structured questionnaires.
Supply-side respondents: production, technical and commercial managers at intermediate manufacturers, prothioconazole technical producers, contract manufacturers, raw-material suppliers and chemical traders.
Demand-side respondents: procurement and R&D professionals at technical producers and formulators, crop-protection distributors, and agronomy specialists.
The objectives of primary research were to verify capacity utilisation and production volumes, understand pricing trends for key intermediates, establish the split of demand by purity grade, assess regional consumption patterns, and capture expectations for the market outlook and competitive developments.
Market Size Estimation
Top-down approach: the global prothioconazole technical market was used as the starting point. Production volumes of prothioconazole technical were estimated by region and converted into intermediate requirements using stoichiometric consumption factors and typical process yields. Intermediate demand was then valued using average intermediate prices by purity grade and region.
Bottom-up approach: the market was built from the supply side by estimating the operating capacity, utilisation and output of identified intermediate producers and integrated technical producers, combined with merchant transaction prices. Country-level estimates were aggregated to regional and global totals.
Data triangulation: the results of both approaches were compared and reconciled. Differences were investigated by revisiting assumptions on yields, captive consumption, purity mix and pricing, and the final estimates were cross-checked against trade data and primary-research inputs.
Forecasting Methodology
The forecast was developed using a factor-based model that links intermediate demand to downstream prothioconazole and other triazolinthione production. Factors considered include crop area and fungicide application intensity for cereals, oilseeds, soybean and corn; disease pressure and resistance-management practices; generic technical capacity additions and utilisation; the trajectory of technical and intermediate prices; regulatory developments, particularly in the European Union; and macroeconomic indicators such as agricultural commodity prices and exchange rates. Historic trends for 2022–2025 were used to calibrate the model, and forecast values were reviewed with industry participants.
Assumptions and Limitations
Market values are expressed in nominal USD Million; currency conversions use annual average exchange rates for the respective year.
Captive consumption of intermediates by integrated technical producers is valued at estimated market-equivalent prices.
Announced capacity projects are included in the forecast only to the extent they are expected to be commissioned and utilised during the forecast period.
The forecast assumes no outright ban of prothioconazole in major markets during the forecast period.
Limited public disclosure by privately held Chinese and Indian producers means that some capacity and pricing data rely on industry estimates.
Unforeseen events such as major plant shutdowns, trade restrictions or extreme weather may cause actual outcomes to differ from the forecast.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The Global Triazolinthione Intermediates Market is moderately fragmented. The originator, Bayer AG, and the backward-integrated generic producer ADAMA Ltd. coexist with a large and growing number of Chinese producers of prothioconazole technical and intermediates. Since the first Chinese technical registrations at the end of 2018, more than 30 technical registrations have been granted in China, and numerous intermediate and technical projects have been announced, many of them in chemical parks in Shandong, Jiangsu, Ningxia, Hubei, Hebei, Gansu and Inner Mongolia.
Competition is based primarily on cost, process efficiency, product purity and impurity control, environmental compliance, the breadth of registrations held by the downstream technical, and the degree of vertical integration. As capacity has expanded faster than demand, price competition has intensified, prompting producers to integrate backward into key intermediates, diversify into other fungicide actives such as SDHIs, and seek differentiation through mixtures and formulation technologies.
Key Player Positioning
Leaders: Bayer AG remains the reference producer, with integrated prothioconazole manufacturing, the broadest portfolio of branded mixtures and a long track record in the chemistry. Bayer reported Group sales of EUR 45.575 billion and Crop Science sales of EUR 21.622 billion for FY2025. Hailir Pesticides and Chemicals Group (FY2025 revenue of RMB 4,202.74 million) and Anhui Jiuyi Agriculture Co., Ltd. (FY2025 revenue of RMB 1,493 million, of which prothioconazole products contributed close to half) are the leading Chinese prothioconazole producers, both operating large-scale technical capacity and pursuing further expansion.
Challengers: ADAMA Ltd. (FY2025 revenue of USD 4,051 million) operates backward-integrated prothioconazole production, including its Taquari plant in Brazil, and supplies proprietary formulations such as ARMERO, SORATEL and AVASTEL. Ningxia Yifan Biotechnology, ABA Chemicals Corporation (FY2025 revenue of RMB 1,307 million), Jiangsu Changqing Agrochemical Co., Ltd. (FY2025 revenue of RMB 3,685.64 million) and Jiangsu Suli Co., Ltd. (FY2025 revenue of approximately RMB 2,777.23 million) are adding prothioconazole capacity and strengthening their positions.
Niche and emerging players: Hebei Xingbai Pharmaceutical Group is building a large prothioconazole project, while Jiangxi Tianxin Pharmaceutical Co., Ltd. (FY2025 revenue of RMB 2,345.04 million) is positioned as an upstream supplier of α-acetyl-γ-butyrolactone, a key starting material for the triazolinthione intermediate chain. Numerous smaller regional intermediate manufacturers in China supply specific steps of the synthesis.
Bargaining power of suppliers: Medium
Key inputs such as ABL and chlorinated aromatics are available from several Chinese producers, limiting individual supplier leverage.
Environmental shutdowns and chemical-park restrictions can temporarily tighten supply and raise prices.
Increasing backward integration by technical producers reduces dependence on external suppliers.
Bargaining power of buyers: High
Buyers are technical producers and formulators, many of them large and able to source from multiple suppliers.
Overcapacity in prothioconazole technical gives buyers strong price leverage.
Integrated producers can switch between captive and merchant supply.
Threat of new entrants: Medium
Numerous Chinese projects demonstrate that entry is feasible once patents expire.
Process know-how, impurity control, environmental approvals and registration requirements remain meaningful barriers.
Falling prices reduce the attractiveness of new entry.
Threat of substitutes: Medium
Alternative DMI fungicides such as tebuconazole, metconazole and mefentrifluconazole, and SDHI or QoI actives, can substitute for prothioconazole in some uses.
Prothioconazole's efficacy against Fusarium head blight and its role in mixtures limit substitution.
Regulatory restrictions on azoles could accelerate substitution in Europe.
Competitive rivalry: High
A large and growing number of Chinese producers compete with Bayer and ADAMA.
Price competition is intense as new capacity is commissioned.
Competitors differentiate on cost, purity, registrations and integration.
Bargaining power of suppliers: Medium; Key inputs such as ABL and chlorinated aromatics are available from several Chinese producers, limiting individual supplier leverage.
Bargaining power of buyers: High; Buyers are technical producers and formulators, many of them large and able to source from multiple suppliers.
Threat of new entrants: Medium; Numerous Chinese projects demonstrate that entry is feasible once patents expire.
Threat of substitutes: Medium; Alternative DMI fungicides such as tebuconazole, metconazole and mefentrifluconazole, and SDHI or QoI actives, can substitute for prothioconazole in some uses.
Competitive rivalry: High; A large and growing number of Chinese producers compete with Bayer and ADAMA.
Market estimates by geography (2032)
InsightAsia Pacific leads with $71.39M by 2032, while Latin America is projected to grow fastest at a 8.4% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $3.27M | $3.98M | $4.95M | 4.2% | 5% |
| Europe | $4.55M | $5.19M | $6.13M | 3.0% | 7% |
| Asia Pacific | $39.48M | $53.45M | $71.39M | 6.1% | 79% |
| Latin America | $2.84M | $4.32M | $6.36M | 8.4% | 7% |
| Middle East & Africa | $0.97M | $1.41M | $2.00M | 7.5% | 2% |
| Total | $51.10M | $68.35M | $90.83M | 5.9% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$90.83M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Prothioconazole | $80.93M | 5.7% | 89% |
| Others | $9.90M | 7.5% | 11% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Triazolinthione Intermediates Market covering market dynamics, competitive landscape, and strategic outlook.
The Triazolinthione Intermediates Market market is projected to reach $90.83M by 2032, growing at 5.9% CAGR. The Prothioconazole segment holds the largest share.
The Global Triazolinthione Intermediates Market is shaped by the interaction of downstream agricultural demand, the industrial economics of prothioconazole manufacturing, and the regulatory environment for crop-protection chemistry. This chapter assesses these forces. The growth factor analysis in Section 4.2 presents analyst assessments of the direction and strength of five macro and five micro factors over three forecast windows; the impact scores (out of 10) are analyst judgements based on secondary and primary research and are intended to indicate relative influence rather than to quantify it.
Expansion of Generic Prothioconazole Production after Patent Expiry
The single most important driver of intermediate demand is the expansion of prothioconazole technical production by generic manufacturers. Prothioconazole was developed by Bayer and commercialised in 2004, and for more than a decade production remained concentrated in the originator's integrated plants. The expiry of the Chinese compound patent in November 2015 and of key process patents thereafter opened the market to generic producers. Anhui Jiuyi Agriculture and Hailir were among the first holders of Chinese technical registrations at the end of 2018, and the number of registrants has since grown substantially; by 2024, China had 32 valid prothioconazole technical registrations. Producers including Hailir, Jiuyi, Ningxia Yifan, ABA Chemicals, Jiangsu Changqing and Jiangsu Suli have commissioned or are building new technical capacity, while ADAMA opened a multi-purpose plant producing prothioconazole in Taquari, Brazil, in 2023. Each tonne of new technical output generates a corresponding requirement for cyclopropyl ketone, hydrazino-alcohol and triazolidinethione intermediates, sustaining volume growth for the intermediates market even as prices decline.
Growing Fungicide Demand in Cereals, Oilseeds and Soybean
Prothioconazole is one of the most widely used fungicides worldwide and is registered in more than 60 countries. Its broad spectrum covers Fusarium head blight, septoria leaf blotch, rusts and powdery mildew in cereals, sclerotinia and phoma in oilseed rape, and Asian soybean rust and other foliar diseases in soybean. Global demand for these crops continues to rise with population growth, dietary change and biofuel use, and growers are increasing fungicide application intensity to protect yield potential and grain quality. Fusarium head blight is of particular importance because of its link to mycotoxin contamination, and prothioconazole is among the most effective actives for its control. In China, the wheat area treated against head blight in 2024 was estimated at around 150 million mu, supporting domestic consumption alongside exports. Expanding soybean and corn acreage in Brazil and Argentina, together with increasing fungicide use in Indian wheat and pulses, further broadens the demand base for triazolinthione intermediates.
Resistance Management and Growth of Mixture Products
The spread of fungicide resistance in key pathogens has made multi-site and multi-mode programmes standard practice. FRAC guidelines encourage the use of DMI fungicides in mixtures with partners from other groups, particularly succinate dehydrogenase inhibitors (SDHIs) and quinone outside inhibitors (QoIs). Prothioconazole has become a preferred DMI partner because of its efficacy and relatively favourable resistance profile compared with older triazoles, and it now features in a wide range of mixtures, including combinations with tebuconazole, trifloxystrobin, bixafen, fluopyram, azoxystrobin and picoxystrobin. New mixture registrations continue to be granted, such as China's first prothioconazole plus picoxystrobin water-dispersible granule registered in July 2025. The proliferation of such products expands the number of formulators requiring prothioconazole technical and, consequently, the demand for its intermediates. Because mixture products typically carry a lower prothioconazole loading per hectare than solo products but are sold across a far wider range of crops and markets, their net effect is to broaden and stabilise demand for technical material, giving intermediate producers greater visibility over offtake volumes.
Increasing Disease Pressure Linked to Climate Variability
Warmer and wetter conditions during flowering and grain fill increase the incidence and severity of Fusarium head blight, rusts and septoria in many cereal-growing regions. Variable weather patterns also extend the period of disease risk and increase the number of fungicide applications required in a season. Agricultural authorities and advisory services in Europe, North America and Asia have repeatedly highlighted the rising frequency of high-disease-pressure seasons. Because prothioconazole is a cornerstone treatment for these diseases, years of high disease pressure translate directly into higher technical demand and, with a short lag, into higher demand for triazolinthione intermediates. Over the forecast period, climate-related disease pressure is expected to provide structural support to fungicide use, particularly in South Asia, Latin America and parts of Africa where fungicide penetration remains comparatively low. Seasonal spikes in demand also encourage formulators and distributors to hold higher safety stocks of technical material, which supports more regular procurement of intermediates by technical producers.
Merchant Supply to New Technical Entrants
Many new prothioconazole technical producers lack integrated access to the cyclopropyl ketone and triazolidinethione stages. This creates an opportunity for specialist intermediate manufacturers that can offer consistent, high-purity material at competitive cost, as well as for contract manufacturers supplying technical producers in India, Brazil and other emerging production centres.
Process Innovation and Cleaner Routes
Patent activity in China shows sustained efforts to improve prothioconazole intermediate routes, including higher-yield preparation of 2-chloro-1-(1-chlorocyclopropyl)ethanone, better control of the desthio impurity and lower-waste oxidation steps. Producers that commercialise cleaner and more efficient processes can gain a cost advantage in a price-competitive market and meet tightening environmental requirements.
Growth in Latin America, South Asia and Africa
Latin America, the Middle East & Africa and South Asia combine expanding crop area, rising fungicide adoption and increasing local formulation and technical manufacturing. Brazil's soybean and corn sectors, India's wheat and rice systems and the cereal belts of South Africa and North Africa offer sustained demand growth for prothioconazole-based products and, by extension, for triazolinthione intermediates supplied into regional manufacturing.
Overcapacity and Price Deflation
Announced and under-construction prothioconazole technical capacity in China far exceeds global demand. Industry estimates published in 2026 put built, under-construction and planned Chinese capacity at more than 78,000 tonnes per year, against global consumption estimated at around 31,000 tonnes or lower. As new plants have come on stream, technical prices have fallen sharply, from around RMB 500,000 per tonne in 2021 to around RMB 130,000 per tonne by November 2025. This price erosion is transmitted upstream to intermediate suppliers, compressing margins, slowing investment in merchant intermediate capacity and restraining the growth of the market in value terms relative to volume.
Regulatory Uncertainty in Europe
Europe is historically one of the largest end-use markets for prothioconazole. Its renewal under Regulation (EC) No 1107/2009 has been prolonged by the assessment of endocrine-disrupting properties, and Commission Implementing Regulation (EU) 2025/787 extended the approval period to 31 March 2027. Although the draft renewal assessment indicated that prothioconazole does not meet the endocrine-disruptor criteria, uncertainty over the final decision, possible restrictions on use conditions and tighter maximum residue levels weigh on long-term planning for both formulators and intermediate suppliers.
Environmental Compliance and Process Hazards
The synthesis of triazolinthione intermediates involves chlorination, Grignard and organometallic chemistry, hydrazine handling and sulphur-based ring formation, generating chlorinated waste streams and requiring careful process-safety management. Stricter environmental enforcement and chemical-park consolidation in China, together with rising compliance costs elsewhere, raise capital and operating costs and can delay project approvals.
Backward Integration by Technical Producers
Leading technical producers are integrating upstream to secure intermediate supply and reduce costs. Hailir has pursued an intermediate-to-technical-to-formulation chain, ADAMA highlights its backward-integrated prothioconazole production, and upstream specialists such as Jiangxi Tianxin are building large α-acetyl-γ-butyrolactone capacity. This trend increases captive consumption and intensifies competition for merchant intermediate suppliers.
Shift toward High-Purity Grades
Technical-equivalence assessments in the EU, Brazil, Australia and other markets require tight control of relevant impurities. Producers are therefore specifying intermediates of 98% & above purity to achieve consistent technical quality, a trend that underpins the faster growth of the high-purity segment.
Differentiated Formulations
Formulators are seeking differentiation through new mixtures and formulation technologies, such as ADAMA's Asorbital prothioconazole formulations and new SDHI and QoI combinations. These products sustain prothioconazole demand despite generic competition.
Challenge: Margin Pressure along the Value Chain
Persistent oversupply has compressed gross margins for technical producers; Anhui Jiuyi's gross margin, for example, fell from 24.66% in 2023 to 18.48% in 2025. Sustaining profitability will require scale, process efficiency and portfolio diversification.
The value chain of the Global Triazolinthione Intermediates Market extends from basic and fine-chemical raw materials through intermediate manufacturing to technical synthesis, formulation and end use in agriculture.
Raw materials and inputs: key inputs include α-acetyl-γ-butyrolactone (ABL), chlorinating agents, 2-chlorobenzyl chloride, magnesium for Grignard reagents, hydrazine hydrate, formaldehyde, thiocyanate salts or sulphur sources, solvents and oxidants. Availability and price of ABL and chlorinated aromatics are important cost determinants; China is the dominant supplier of most inputs.
Intermediate manufacturing: ABL is converted to cyclopropyl ketone intermediates such as 1-chloro-1-acetylcyclopropane and 2-chloro-1-(1-chlorocyclopropyl)ethanone, which are coupled with the chlorophenyl moiety to form oxirane and propanol intermediates. Reaction with hydrazine yields hydrazino-alcohol intermediates, which are cyclised to triazolidine-3-thione precursors. This stage requires process know-how, impurity control and environmental management, and is carried out both by specialist intermediate makers and by integrated technical producers.
Technical synthesis: the triazolidinethione precursor is oxidised to prothioconazole technical, which is purified to specification (typically 95–98% minimum active content). Technical producers register their material in target markets and supply it to formulators.
Distribution and channels: intermediates move through direct contracts between manufacturers and technical producers, through chemical traders and exporters, and through intra-group transfers in integrated companies. Technical material is sold to multinational and regional formulators.
End users: formulated prothioconazole products, alone or in mixtures, are applied by farmers on cereals, oilseed rape, soybean, corn, peanuts and other crops, and as seed treatments, through agrochemical distributors and retailers.
Triazolinthione intermediates are subject to chemical-control regulations at the manufacturing and trade stage, while their downstream value depends on the registration status of prothioconazole and related actives under pesticide laws.
North America
United States: pesticide products are registered by the EPA under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA); residue tolerances are set under the Federal Food, Drug, and Cosmetic Act (FFDCA); industrial chemicals, including intermediates, are governed by the Toxic Substances Control Act (TSCA). Prothioconazole received EPA registration in 2007.
Canada: pest control products are regulated by Health Canada's Pest Management Regulatory Agency (PMRA) under the Pest Control Products Act.
Mexico: pesticide registration is administered by COFEPRIS together with the agriculture and environment authorities.
Europe
Regulation (EC) No 1107/2009 governs the approval of active substances and authorisation of plant-protection products. Prothioconazole's approval was extended to 31 March 2027 by Commission Implementing Regulation (EU) 2025/787 pending completion of the renewal.
Regulation (EC) No 396/2005 sets maximum residue levels for pesticides in food and feed.
REACH (Regulation (EC) No 1907/2006) and CLP (Regulation (EC) No 1272/2008) apply to the manufacture, import and classification of chemical intermediates in the EU.
United Kingdom: active substances are regulated by the Health and Safety Executive under retained plant-protection legislation and UK REACH.
Asia Pacific
China: the Regulations on Pesticide Administration (revised 2017) require registration of technical and formulated products with ICAMA and production licensing; new chemical plants require environmental impact assessment approval.
India: the Insecticides Act, 1968 and Insecticides Rules, 1971 govern registration by the CIB&RC, including registration of indigenously manufactured technical material.
Japan: the Agricultural Chemicals Regulation Act governs pesticide registration; the Chemical Substances Control Law applies to industrial chemicals.
Australia: the Australian Pesticides and Veterinary Medicines Authority (APVMA) registers agricultural chemicals under the Agricultural and Veterinary Chemicals Code.
Latin America
Brazil: Law No. 14,785/2023 established the current pesticide regulatory framework, with registration coordinated by MAPA together with ANVISA and IBAMA.
Argentina: plant-protection products are registered by the National Agri-Food Health and Quality Service (SENASA).
Middle East & Africa
South Africa: agricultural remedies are registered under the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act No. 36 of 1947).
Gulf states: pesticide registration is managed by national agriculture and environment ministries, with harmonisation efforts under the Gulf Cooperation Council.
Dec 2022: Hailir Pesticides and Chemicals Group; Expansion; New prothioconazole technical line at Shandong Hailir entered trial production, adding 3,000 tonnes per year of capacity.
Feb 2023: ADAMA Ltd.; Expansion; Opened a multi-purpose plant in Taquari, Brazil, with an investment of more than USD 50 million, producing prothioconazole for its global portfolio.
Feb 2023: Hebei Xingbai Pharmaceutical Group; Expansion; Started a 10,000 tonnes per year prothioconazole project, comprising a 3,000-tonne Phase I and a 7,000-tonne Phase II.
Apr 2023: ADAMA Ltd.; Product Launch; Promoted SORATEL and MAGAN prothioconazole formulations based on its Asorbital technology in the U.K.
Jun 2023: Ningxia Yifan Biotechnology; Expansion; Commenced production at a 1,500 tonnes per year prothioconazole technical plant.
Feb 2024: Jiangsu Suli Co., Ltd.; Expansion; Shareholders approved raising the prothioconazole capacity in its fundraising project from 1,000 to 2,000 tonnes per year.
Mar 2024: ABA Chemicals Corporation; Expansion; Published environmental-impact notice for a 2,000 tonnes per year prothioconazole expansion at Yangkou Chemical Park, Rudong.
Apr 2024: Jiangxi Tianxin Pharmaceutical Co., Ltd.; Expansion; Ningxia Tianxin project published, including 26,000 tonnes per year of α-acetyl-γ-butyrolactone, a key prothioconazole intermediate.
Apr 2025: Hailir Pesticides and Chemicals Group; Expansion; Qingdao Hengning Phase II project includes 10,000 tonnes per year of prothioconazole technical capacity.
Jul 2025: Ningxia Yifan Biotechnology; Product Launch; Group company Jiangsu Yunfan Chemical received China's first registration for a prothioconazole plus picoxystrobin water-dispersible granule.
Aug 2025: Jiangsu Changqing Agrochemical Co., Ltd.; Expansion; Redirected fundraising proceeds to a 1,000 tonnes per year prothioconazole technical project in Yichang, Hubei.
Nov 2025: ABA Chemicals Corporation; Expansion; 2,000-tonne prothioconazole technical capacity at Nantong Yaben entered trial production.
Q4 2025: ADAMA Ltd.; Product Launch; Obtained registrations for AVASTEL in Hungary, Austria and the Netherlands and for SORATEL in Estonia.
May 2026: Anhui Jiuyi Agriculture Co., Ltd.; Corporate; Refiled its IPO application to fund a 6,000 tonnes per year fungicide technical plant; the review was terminated in September 2026.
Political
Food-security policies in China, India and the Gulf states support domestic crop-protection supply chains.
Trade tensions and tariff measures affect the flow of Chinese intermediates and technicals to the United States and other markets.
Industrial policy in China encourages consolidation of chemical producers into approved chemical parks.
Economic
Agricultural commodity prices influence farmer spending on fungicides and hence technical demand.
Overcapacity has driven prothioconazole technical prices down sharply since 2021.
Currency movements, particularly the Chinese renminbi, affect export competitiveness.
Social
Growing consumer focus on mycotoxin-free grain supports the use of effective Fusarium fungicides.
Public concern over pesticide residues influences regulatory and retailer requirements in Europe.
Farmer education programmes are increasing fungicide adoption in emerging markets.
Technological
Process innovations improve yields and reduce impurities in cyclopropyl ketone and thione-forming steps.
Continuous-flow and catalytic processes are being explored to reduce waste and improve safety.
New formulation technologies extend the commercial life of prothioconazole.
Environmental
Chlorinated waste streams and solvent use require advanced effluent treatment.
Environmental-impact-assessment requirements govern the approval of new capacity in China.
Climate change is increasing fungal disease pressure on major crops.
Legal
Patent expiry has opened the market to generic producers.
EU renewal of prothioconazole under Regulation (EC) No 1107/2009 remains pending.
Technical-equivalence and data-protection rules shape market access for generic technical material.
Profiles of 105 companies operating in the Triazolinthione Intermediates Market market, including revenue, employee count, and market positioning where available.
Showing 105 of 105 companies
ADAMA is the world's leading pure-play off-patent crop protection company and the "value" arm of Syngenta Group. It does not discover new chemistry at the scale of the research majors; instead it takes active ingredients that have lost or are about to lose patent protection and re-engineers them through proprietary formulation platforms (Asorbital, Sesgama, T.O.V., Desidro, Ayalon) into mixtures that offer growers a measurable agronomic benefit at a lower price point than originator brands. It sells roughly USD 4 billion a year of herbicides, insecticides and fungicides, with a balanced footprint across Europe, North America, Latin America and Asia-Pacific, backed by back-integrated synthesis in Israel, China and Brazil. After a severe 2023–2024 downturn caused by channel destocking and Chinese active-ingredient overcapacity, the "Fight Forward" programme has restored margins and cash generation, although statutory earnings only turned positive in the first half of 2026 and leverage remains elevated. --- **What the company says.** In its results releases ADAMA describes itself as a global crop protection leader that supplies practical solutions to farmers for weeds, insects and disease, built on a diverse portfolio of existing active ingredients, formulation capability and proprietary formulation technology platforms. It states that it serves customers in dozens of countries with a direct presence in all of the top 20 agricultural markets (FY2025 PR, "About ADAMA"). Earlier boilerplate (FY2022 PR) referred to sales in more than 100 countries; the narrower current wording is consistent with the Fight Forward decision to concentrate on priority countries. **Independent characterisation.** ADAMA is an integrated post-patent agrochemical manufacturer and marketer. Its economics rest on four activities: 1. **Registration and regulatory work.** Value in off-patent crop protection is gated by product registrations country by country. ADAMA obtained 174 new registrations in 2025 and maintains a registration network covering more than 80 countries (2025 Annual Report, as summarised by Sohu Finance and Dongxing Securities). 2. **Formulation and mixture design.** The company manages more than 300 active ingredients centrally and about 1,300 end-use mixtures and formulations (Dongxing Securities note of 7 April 2026, citing the 2025 Annual Report). "Differentiated" products accounted for 45% of crop protection sales excluding active-ingredient sales in 2025. 3. **Manufacturing.** Synthesis of selected active ingredients and formulation at sites principally in Israel, China and Brazil (FY2025 PR). The company has moved away from producing certain basic chemicals in China and is explicitly shifting to a more flexible, asset-light supply network (H1 2026 PR). 4. **Go-to-market.** Sales are made mainly to distributors, retailers and cooperatives, with farmer-facing demand generation in priority markets. A smaller Consumer & Professional Solutions business in North America sells home, garden and professional pest-control products. **Revenue model.** Revenue is almost entirely product sales. There is no material subscription, licensing or service revenue disclosed; the December 2025 BASF agreement on Gilboa introduces a co-development and commercialisation arrangement whose financial terms are not publicly disclosed. In FY2025, Crop Protection contributed USD 3,730 million (92%) and Intermediates & Ingredients USD 321 million (8%) (FY2025 PR). **Value chain position.** ADAMA sits between upstream chemical intermediates suppliers (largely Chinese) and agricultural distribution. It is partially back-integrated into chlor-alkali and key intermediates, and buys a significant share of technical-grade active ingredients externally. This makes gross margin sensitive to the timing gap between falling procurement costs and falling selling prices, visible in the margin compression of 2023 and the recovery of 2024–2025. **Customers and end-markets.** End-users are growers of row crops (soybean, corn, cereals, cotton, rice, sugarcane), fruit and vegetables, and speciality crops. Non-agricultural customers include consumer and professional pest-control channels in North America and industrial buyers of intermediates, aroma chemicals and other non-ag products.
Bayer is a German life-science group with three businesses: Crop Science, Pharmaceuticals and Consumer Health. It is the world's largest combined seed, trait and crop-protection supplier, a mid-sized prescription-drug maker, and a top-five self-care company. Fiscal 2025 sales were EUR 45.6 billion. The 2018 purchase of Monsanto brought leading corn and soybean genetics but also glyphosate and PCB litigation, which has consumed well over EUR 10 billion in settlements and produced net losses in 2023, 2024 and 2025. Under CEO Bill Anderson the company has cut management layers, held the dividend at the legal minimum, and concentrated on four priorities: rebuilding the pharma pipeline, containing litigation, reducing debt and improving crop profitability. In 2026 a 7–2 U.S. Supreme Court ruling on federal pre-emption and a proposed USD 7.25 billion class settlement moved the litigation closer to resolution, though the settlement still awaits final court approval. --- **Company's own description.** Bayer describes itself as a global enterprise with core competencies in the life-science fields of health care and nutrition, operating under the mission "Health for all, Hunger for none" (Annual Report 2025; press boilerplate 2026). Bayer AG is a holding company; operations sit in subsidiaries worldwide. In fiscal 2025 the Group had about 88,000 employees, sales of EUR 45.6 billion and R&D expenses of EUR 5.8 billion. **Independent characterisation.** Bayer is best understood as three distinct businesses sharing a balance sheet, a brand and a legal liability. Crop Science (47 percent of FY2025 sales) is an input supplier to farmers. It earns money from proprietary seed and biotech traits, from chemical and biological crop protection, and to a small extent from digital farming subscriptions. Seed and trait revenue carries royalty-like economics: Bayer licenses traits to other seed companies, and two licensing settlements with Corteva lifted results in Q4 2025 and Q1 2026. The business is strongly seasonal, with Northern Hemisphere sales concentrated in the first half and Latin American sales in the second. Pharmaceuticals (39 percent of sales) discovers, develops and sells prescription medicines, concentrated in cardiovascular and renal disease, oncology, women's health and ophthalmology, plus a radiology unit selling contrast agents and injector hardware. Revenue is almost entirely product sales, with some licence income (for example U.S. Xarelto royalties from Johnson & Johnson, and Eylea outside the United States under a collaboration with Regeneron). The division is in the middle of a patent transition: Xarelto and Eylea are declining while Nubeqa and Kerendia are growing quickly. Consumer Health (13 percent of sales) sells non-prescription brands through pharmacies, mass retail and e-commerce. It is a branded consumer-goods model with stable margins and low capital intensity. **Revenue model mix.** Bayer does not disclose a product/service/licensing split. On the evidence of the Annual Report 2025, the large majority of revenue is product sales; licensing income is embedded in Crop Science seed and trait lines and in Pharmaceuticals; subscription revenue (Climate FieldView, radiology software) is immaterial at Group level. An exact percentage split is not publicly disclosed. **Value-chain position.** Bayer is a research-based originator and manufacturer. It owns discovery, development, active-ingredient and finished-product manufacturing, and commercial organisations, and sells through distributors, retailers, wholesalers, hospitals and pharmacies rather than directly to end users in most markets. **Customers and end markets.** Farmers, agricultural retailers and distributors, and seed licensees (Crop Science); wholesalers, hospitals, physicians, pharmacy chains, governments and payers (Pharmaceuticals); pharmacies, supermarkets, drugstores and online retailers (Consumer Health).
DuPont de Nemours today is a focused, roughly USD 7 bn-revenue multi-industry company. It is no longer the diversified chemical conglomerate of its heritage. After a decade of portfolio surgery, the company consists of two segments: **Healthcare & Water Technologies (about 47% of FY2025 sales):** Tyvek® medical packaging and protective garments, specialty medical device components (Spectrum, Donatelle), and the FilmTec™ / Amberlite™ water purification franchise. **Diversified Industrials (about 53%):** Building envelope products (Tyvek® house wrap, Styrofoam™, Corian®) and engineered industrial technologies (Molykote®, Vespel®, Betaseal™/Betaforce™ adhesives, Cyrel® printing plates). The company earns a premium-specialty margin profile: operating EBITDA margin was 23.8% in FY2025, with guidance of about 24.5% for FY2026. Management targets 3–4% organic growth, 150–200 bps of margin expansion and 8–10% adjusted EPS CAGR through 2028, supported by a lightly levered BBB+/Baa1 balance sheet. The principal overhang is legacy PFAS liability, shared with Chemours, Corteva and Qnity under contractual arrangements. The principal opportunity is a cleaner, higher-growth healthcare/water mix and capital redeployment. --- **Company's own description (FY2025 10-K, Item 1).** DuPont describes itself as a leading provider of advanced solutions that improve everyday life across healthcare, water, construction and industrial markets. It emphasizes helping customers advance their technology pipelines, from clean water to medical packaging that enhances safety and performance. It names its competitive strengths as: - proprietary product and process technologies; - robust application-development pipelines; - well-known brands; - customer intimacy; - global manufacturing and local service capability. **Independent characterization.** DuPont is now best understood as a specialty engineered-materials and components company with four businesses of roughly comparable scale: **Business model and revenue model.** - Revenue is overwhelmingly product sales: materials, components, membranes, resins, garments and plates. Some engineered systems and modules are sold in Water. - There is no material subscription or licensing revenue. Trade secrets may be licensed occasionally (10-K, Intellectual Property). - The contract manufacturing and design services of Spectrum and Donatelle (medical devices) add a design-in / build-to-print services element, but are recognized as product revenue. - Seasonality: North American Building Technologies demand peaks in Q2–Q3. **Value-chain position.** DuPont sits mid-stream as a Tier-1/Tier-2 supplier. It converts purchased raw materials (polyolefins, specialty monomers, resins, silicones, polymers) into engineered materials, membranes and components. These are specified into customers' finished products: medical devices, sterile packaging, water plants, building envelopes, aircraft, vehicles and print packaging. **Customer types.** - Medical device OEMs and sterile packaging converters - Biopharma manufacturers - Industrial end users and EPC/OEM water-system integrators - Municipalities and desalination operators (via integrators) - Builders, contractors and distributors (e.g., Corian® distribution through Hallmark and Parksite) - Automotive and EV OEMs and Tier-1s - Aerospace OEMs - Printing and packaging converters Most products are sold through DuPont's own sales organization, with distributors used for some lines (10-K, Distribution). **End markets.** Healthcare (medical devices, packaging, biopharma, PPE), water (industrial, municipal/desalination, life sciences, microelectronics UPW), construction (residential, non-residential, repair/remodel) and industrial (aerospace, automotive/EV, printing and packaging, general industrial).
3 interactive charts drawn from the Triazolinthione Intermediates Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Triazolinthione Intermediates Market By Purity
Global Triazolinthione Intermediates Market By Downstream Product
Global Triazolinthione Intermediates Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
